Recently, Roche acquired Adheron Therapeutics with $580 million for enhancing the immune research.

The shareholders of Adheron Therapeutics get $150 million cash, the other $475 million will be paid after they achieve a specific goal.

By this acquisition, Roche will get Adheron’s research plan: SDP051. It’s especially for a protein called Cadherin-11, which have passed the first stage of a research project.

Cadherin-11 plays an important role in this research project, Adheron wanted to use this new formula to get success in autoimmune diseases such as the treatment of rheumatoid arthritis.